Learn more about investing in Particella

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
Particella
Particella
Oral Gene Medicines
INVESTOR INQUIRIES
Biopharma Human Health Therapeutics IBSF05 2017 Seed Human Health 100 United States
* Data source: Crunchbase
Founded
2016
Employees*
2-10
Website
particella.bio
* Data source: Crunchbase

Particella Inc., (formerly DNAlite Therapeutics) is a biotechnology company that has developed a novel proprietary lipid nanoparticle that can deliver mRNA and other nucleic acids orally.

Team
Mubhij Ahmad
CEO & Co-Founder
Timothy Day
CSO & Co-Founder
Company News
global university venturing | August 10, 2018
DNAlite musters $1.5m seed round
Global University Venturing
PE Hub | August 08, 2018
DNAlite Therapeutics fetches $1.5 mln
DNAlite Therapeutics Inc, an gastrointestinal gene therapy biotech startup, has raised $1.5 million in seed financing. Berkeley Catalyst Fund led the round with participation from University of California Berkeley, Blue Bear Ventures, SOSV, the Baldota family, BrightGene and SVE Capital.
businesswire | July 15, 2020
New Partner Arvind Gupta & Genesis Consortium Reflect Mayfield's Commitment to Human and ...
SEE ALL NEWS